Dupilumab will dominate sales in the atopic dermatitis market by addressing key unmet needs for patients.
By Christina Vasiliou, Senior Analyst
11 April 2016
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
Datamonitor Healthcare anticipates that dupilumab, the first biologic expected to be approved for atopic dermatitis, will dominate sales in the market by 2024. Datamonitor Healthcare surveyed 216 dermatologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to size the atopic dermatitis market opportunity and gain an understanding of current and future prescribing patterns. Surveyed dermatologists hold a positive outlook for dupilumab, based on its promising clinical performance to date, and eagerly anticipate its approval as it has the potential to address a high burden in the treatment of atopic dermatitis by providing a targeted therapy suitable for severe patients who are not adequately controlled on topical corticosteroids. While dupilumab’s anticipated high price will relegate it to late lines of therapy, it will also mean that Sanofi and Regeneron will see relatively high returns. Datamonitor Healthcare expects dupilumab to drive growth in the atopic dermatitis market over 2015–24.
“I think dupilumab is a breakthrough, I mean it will be the first biologic, which will hopefully come to the market; it is the first in class, and there are major hopes put into this new product. It will certainly be a breakthrough, at least for the moderate to severe population.”
– EU key opinion leader
The above is excerpted from Datamonitor Healthcare’s Atopic Dermatitis: Forecast, which uses a patient-based approach to size the atopic dermatitis market opportunity across the US, Japan, and five major EU markets during 2015–24.
Get your free demo today – simply fill in the form to the right.